EarliPoint Health Launches the Developmental Progress Report to Show Change Across Assessments in Autism Care.

Learn More →

ABLLS-R + Objective Developmental Data: Building a Modern Assessment Stack

On This Page

The ABLLS-R gives ABA teams something no device can: a detailed, teachable inventory of 544 skills, directly linked to curriculum. It tells you what a child can do and what to teach next. What it doesn’t produce — and was never designed to produce — is an objective, rater-independent measure of the child’s development.

This article looks at how the two kinds of measurement differ, why a growing number of practices are running them side by side, and what an ABLLS-R-plus-objective-data assessment stack looks like in practice. If you’re newer to the ABLLS-R itself, start with our complete guide to the ABLLS-R.

Two Different Questions

Every assessment answers a question. Mixing up which tool answers which question is where assessment stacks go wrong.

The ABLLS-R answers: What skills does this child have, and what should we teach next? It’s criterion-referenced and curriculum-linked — the bridge between assessment and programming. Scoring is based on direct observation by a clinician, supplemented by caregiver input.

Objective developmental measurement answers: How is this child’s underlying development changing — measured the same way, every time, independent of who is in the room? This is the question device-based measurement was built for.

Neither replaces the other. A skills inventory can’t be generated by a device, and a clinician-scored protocol can’t produce rater-independent data. The question is whether your assessment stack answers both questions — or only the first.

Where Clinician-Scored Assessments Have Structural Limits

The ABLLS-R’s strengths come from clinical judgment — and that’s also its boundary. Three characteristics matter for teams thinking about measurement quality:

  1. Scoring runs through an observer. Skilled assessors usually converge, but the data still reflects a person’s judgment about performance, and different assessors across a multi-year program introduce variability.
  2. It measures performance, not process. A skill grid captures what the child did during structured tasks. It does not directly quantify social visual engagement or attentional processes — the developmental processes underneath skill acquisition. It’s time-intensive to administer fully. Depending on the child’s skills and the amount of direct testing required, a comprehensive initial ABLLS-R may take many hours across multiple sessions. That’s justified for programming — but it means teams understandably reassess selectively, which limits how consistent the longitudinal record is.

None of this argues against the ABLLS-R. It argues for pairing it with a measurement layer that has the opposite properties: brief, standardized, and independent of the rater.

What the Objective Layer Adds

The EarliPoint System is an FDA-cleared medical device indicated for use as a tool to aid qualified clinicians in the diagnosis and assessment of ASD in children 16 to 95 months old who are at risk based on concerns shared by a parent, caregiver, or healthcare provider. During an assessment, the child watches short videos of social scenes while eye-tracking sensors measure looking behavior moment to moment. The technology is built on two decades of published social visual engagement research, with diagnostic accuracy studies published in JAMA.

Alongside an ABLLS-R-driven program, it adds three things:

  • A rater-independent data point. The device measures the child directly — same measurement method at every administration, regardless of who administers it.
  • A developmental complement to the skills picture. Indices related to social engagement provide context the skill grid doesn’t capture.
  • Low administration burden. The child watches a video; there are no task demands to run. Clinician time goes to interpretation rather than administration.

The framing that matters: this is an additive layer, not a substitute. Practices keep the ABLLS-R exactly as it is — it remains the programming engine. The objective layer sits alongside it in the assessment battery.

What the Combined Stack Looks Like in Practice

A representative structure many teams converge on:

Layer Tool Question It Answers Cadence
Skills & Curriculum ABLLS-R (or VB-MAPP) What to teach next Initial + periodic targeted reassessment
Adaptive Function Vineland-3 or similar Everyday functioning vs. age norms Per program requirements
Objective Developmental Measure EarliPoint Rater-independent data at assessment checkpoints Per clinician judgment, within the cleared indication

Each layer covers a blind spot in the others: the skill grid is teachable but observer-scored; the adaptive scale is norm-referenced but report-based; the device measure is objective but isn’t a curriculum. Together, they give the clinical team — and the family — a fuller picture than any one tool produces alone.

Frequently asked questions

Does objective measurement replace the ABLLS-R?

No. The ABLLS-R is a skills assessment and curriculum guide; device-based measurement doesn’t generate teaching targets. The two answer different questions and are used together.

Is the ABLLS-R objective?

The ABLLS-R is systematic and structured, but scoring is based on clinician observation and judgment. That’s appropriate for its purpose. “Objective” in the measurement sense — device-measured, rater-independent — describes a different category of data.

What is the EarliPoint System?

An FDA-cleared medical device indicated for use as a tool to aid qualified clinicians in the diagnosis and assessment of ASD in children 16 to 95 months old who are at risk. The child watches short videos of social scenes while the device measures looking behavior. It complements, rather than replaces, clinical judgment and established assessment practices.

Can the two be used in the same assessment cycle?

Yes. Because the device assessment is brief and places no task demands on the child, practices typically schedule it within existing assessment checkpoints without restructuring the ABLLS-R workflow.

 

Angela Pagliaro, LBA, BCBA

Solutions Consultant

Angela is a Solutions Consultant at Earlipoint Health with expertise in applied behavior analysis and healthcare operations.

Angela Pagliaro, LBA, BCBA

Solutions Consultant

Angela is a Solutions Consultant at Earlipoint Health with expertise in applied behavior analysis and healthcare operations.

See how EarliPoint fits seamlessly into your clinical workflow.

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder